Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

Jun 14 2013

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Policy & advocacy

Our mandateEHA’s policy and advocacy work is guided by the European Affairs Committee, which sets the priorities, formulates positions and actively contributes to engagement with policy makers and stakeholders.

Presidential Speakers

Promising crucial developments in the field of hematology, the speakers and presentation topics of the EHA2025 Presidential Session speakers are now available.

Friday, June 13, 2025 - Presidential Session I

Immunotherapy (TCR related)

Prof.

Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe

Jun 12 2015

Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.